Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist's Perspective

about

Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist's Perspective

Item

http://www.wikidata.org/entity/Q57652415

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в березні 2018

@uk

name

Timing of Anticoagulation for ...... talian Internist's Perspective

@en

Timing of Anticoagulation for ...... talian Internist's Perspective

@nl

type

Item

label

Timing of Anticoagulation for ...... talian Internist's Perspective

@en

Timing of Anticoagulation for ...... talian Internist's Perspective

@nl

prefLabel

Timing of Anticoagulation for ...... talian Internist's Perspective

@en

Timing of Anticoagulation for ...... talian Internist's Perspective

@nl

P1476

Timing of Anticoagulation for ...... talian Internist's Perspective

@en

P2093

Nicoletta Riva

http://www.w3.org/2001/XMLSchema#string

Walter Ageno

http://www.w3.org/2001/XMLSchema#string

P2860

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry.

Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation.

Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis.

Spontaneous bleeding or thrombosis in cirrhosis: What should be feared the most?

Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis.

Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies.

Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.

Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban.

P304

6-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2478/JTIM-2018-0002

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29607297

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

thrombosis

anticoagulation

P932

5874480

http://www.w3.org/2001/XMLSchema#string